Andere Sprachen Achilles Therapeutics plc

Aktien

A3CUPM

US00449L1026

ACHL

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 01.05.2024			% 5 Tage	% 1. Jan.
0,7818 ^USD	+4,24 %		-0,26 %	-12,06 %

05.04.	ACHILLES THERAPEUTICS PLC : Chardan Research gibt eine Kauf-Bewertung ab	ZM
05.04.	ACHILLES THERAPEUTICS PLC : Von Piper Sandler auf neutral reduziert	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

ADRs Close Lower; Moatable Inc. Declines 33.3%	04.04.
Syncona notes investee Achilles's annual loss narrows	04.04.
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights	04.04.
Achilles Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	04.04.
Achilles Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04.04.
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	04.04.
Achilles Therapeutics plc Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	04.04.
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference	05.02.
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction	18.12.
Syncona notes investee company's quarterly loss	14.11.
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights	13.11.
Achilles Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	22.09.23
Syncona's portfolio Achilles Therapeutics net loss narrows	04.08.23
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights	04.08.23
Achilles Therapeutics : Corporate Presentation – August 2023	04.08.23
Achilles Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04.08.23
Achilles Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K	29.06.23
IO Summit EU 2023 - Personalised Neoantigen Therapies: State of the Art Neoantigen Immunogenicity Prediction	22.06.23
Achilles Therapeutics : SAE Cell and Gene Therapy 2023 - Targeting Clonal Neoantigens in Cancer	22.06.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Achilles Therapeutics plc

Aktien

A3CUPM

US00449L1026

ACHL

Andere Sprachen

Filter